» Articles » PMID: 28018010

Uveal Melanoma Cell Lines: Where Do They Come From? (An American Ophthalmological Society Thesis)

Overview
Specialty Ophthalmology
Date 2016 Dec 27
PMID 28018010
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether some of the most often used uveal melanoma cell lines resemble their original tumor.

Methods: Analysis of the literature, patient charts, histopathology, mutations, chromosome status, HLA type, and expression of melanocyte markers on cell lines and their primary tumors. We examined five cell lines and the primary tumors from which they were derived.

Results: Four of the five examined primary tumors were unusual: one occupied the orbit, two were recurrences after prior irradiation, and one developed in an eye with a nevus of Ota. One cell line did not contain the GNA11 mutation, but it was present in the primary tumor. Three of the primary tumors had monosomy 3 (two of these lacked BAP1 expression); however, all five cell lines showed disomy 3 and BAP1 expression. All of the cell lines had gain of 8q. Two cell lines lacked expression of melanocyte markers, although these were present in the corresponding primary tumor.

Conclusions: All cell lines could be traced back to their original uveal melanoma. Four of the five primary tumors were unusual. Cell lines often differed from their primary tumor in chromosome status and melanocyte markers. However, their specific chromosome aberrations and capacity to continue proliferation characterize them as uveal melanoma cell lines.

Citing Articles

Co-isolation of human donor eye cells and development of oncogene-mutated melanocytes to study uveal melanoma.

Chen Y, Jin E, Abdouh M, Bonneil E, Jimenez Cruz D, Tsering T BMC Biol. 2025; 23(1):16.

PMID: 39838458 PMC: 11752652. DOI: 10.1186/s12915-025-02118-w.


Novel Uveal Melanoma Patient-Derived Organoid Models Recapitulate Human Disease to Support Translational Research.

Dalvin L, Andrews-Pfannkoch C, Miley D, Hogenson T, Erickson S, Malpotra S Invest Ophthalmol Vis Sci. 2024; 65(13):60.

PMID: 39601636 PMC: 11605663. DOI: 10.1167/iovs.65.13.60.


Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines.

Ferrier S, Li M, Burnier J BMC Cancer. 2024; 24(1):1299.

PMID: 39434038 PMC: 11495039. DOI: 10.1186/s12885-024-13037-4.


Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma.

Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S Br J Cancer. 2024; 131(11):1846-1857.

PMID: 39394450 PMC: 11589887. DOI: 10.1038/s41416-024-02866-6.


The Phenotypical Characterization of Dual-Nature Hybrid Cells in Uveal Melanoma.

Marcotte E, Goyeneche A, Abdouh M, Burnier J, Burnier Jr M Cancers (Basel). 2024; 16(18).

PMID: 39335202 PMC: 11429545. DOI: 10.3390/cancers16183231.


References
1.
Sisley K, Rennie I, Parsons M, Jacques R, Hammond D, Bell S . Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997; 19(1):22-8. DOI: 10.1002/(sici)1098-2264(199705)19:1<22::aid-gcc4>3.0.co;2-2. View

2.
de Waard-Siebinga I, Blom D, Griffioen M, Schrier P, Hoogendoorn E, Beverstock G . Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995; 62(2):155-61. DOI: 10.1002/ijc.2910620208. View

3.
Singh A, De Potter P, Fijal B, Shields C, Shields J, Elston R . Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology. 1998; 105(1):195-8. DOI: 10.1016/s0161-6420(98)92205-9. View

4.
Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N . Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013; 45(8):933-6. PMC: 4307600. DOI: 10.1038/ng.2674. View

5.
Ambrosini G, Sawle A, Musi E, Schwartz G . BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells. Oncotarget. 2015; 6(32):33397-409. PMC: 4741774. DOI: 10.18632/oncotarget.5179. View